Top NYC, NY Pharma Companies With Best Stability & Growth (109)

Strong Market Position & Advantage: Broad adoption across large pharma and recognition as a leader in physics‑based discovery software indicate a durable competitive edge, reinforced by flagship tools like Glide and FEP+ with peer‑reviewed validation. Penetration across all top global pharma and sticky, long‑tenure accounts suggest standard‑tool status in discovery teams.

Strong Revenue Growth: Recent results show higher software revenue and total revenue growth in 2025, with guidance pointing to continued expansion in software ACV in 2026. Management frames software as the scaled growth engine while hosted deployments rise.

Strategic Partnerships: Large, multi‑year collaborations with major pharmas and long‑running technical work with NVIDIA support pipeline upside and platform performance. Deal structures with upfronts, milestones, and potential royalties diversify growth levers.

Strong Market Position & Advantage: Industry analyses and company disclosures depict GoodRx as the leading U.S. prescription discount and price-comparison platform by scale, usage, and brand visibility. This position is reinforced by broad pharmacy acceptance and sustained revenue at national scale.

Diversified Revenue Streams: Management is expanding beyond coupons into manufacturer programs, subscriptions, telehealth, and integrated point‑of‑sale savings. Rapid growth in manufacturer solutions has begun to counterbalance softness in legacy transactions.

Strategic Partnerships: Collaborations with major drug manufacturers and PBM/pharmacy programs (e.g., insulin affordability and biosimilar cash‑price offerings, integrated savings at checkout) extend distribution and deepen ecosystem integration. These relationships enhance consumer access and relevance with pharma and retail stakeholders.

Strong Market Position & Advantage: Industry tallies continue to place Pfizer among the global top tier by pharmaceutical revenue and scale, with company guidance keeping it one of the largest drugmakers by sales. Leadership by platforms and global footprint is reinforced by sustained positions in major rankings and markets.

Diversified Revenue Streams: The portfolio spans vaccines (e.g., Prevnar/Prevenar, Abrysvo), cardiovascular/rare disease (Eliquis alliance, Vyndaqel), oncology (legacy brands plus Seagen assets), and anti-infectives, providing multiple contributors as COVID revenues normalize. Product mix in 2025 highlighted several sizable non-COVID franchises supporting the base business.

Future-Ready Strategy: Management emphasizes oncology expansion via the Seagen acquisition, a broad late-stage pipeline with many pivotal starts slated for 2026, and cost/operations programs to fund R&D. These actions are positioned to drive a late‑decade growth reacceleration as near-term headwinds abate.

Strong Revenue Growth: The company experienced a notable reacceleration in 2024 largely driven by its GLP‑1‑centered Ro Body program. Additional product launches and access to new GLP‑1 formats further supported momentum into 2025–2026.

Strategic Partnerships: Ro secured first‑tier manufacturer relationships around GLP‑1 therapies, including integrations for Zepbound and Wegovy and participation in the Wegovy pill launch. These partnerships expand access and channel credibility in obesity care.

Strong Market Position & Advantage: Ro operates a vertically integrated platform spanning telehealth, labs/diagnostics, and owned pharmacy fulfillment, reinforced by acquisitions like Workpath, Kit, and Modern Fertility. This end‑to‑end stack and nationwide reach underpin leadership claims within its DTC niche.

Strong Market Position & Advantage: Flatiron is broadly regarded as a leader in oncology-focused RWD/RWE, anchored by a deep oncology EHR footprint, regulatory-grade curation, and a long track record collaborating with regulators and major biopharma. Frequent large-scale dataset releases and sustained presence at major congresses (e.g., ASCO 2025) reinforce this standing.

Strategic Partnerships: FDA has repeatedly partnered with Flatiron on oncology RWE methods and endpoints with renewals/expansions, and collaborations with leading organizations (e.g., Unicancer, Japan’s NCCHE) extend its ecosystem reach. These relationships signal methodological trust and strengthen access to high-value research opportunities.

Product Line Growth: New large-scale datasets, including six hematology cohorts covering roughly 505k patients in 2025, show continued expansion of evidence products. An active cadence of publications and presentations indicates sustained product momentum.

Investor Backing & Capital Strength: Raised a $372M Series D in June 2024 led by Andreessen Horowitz with Sanofi participating, placing it among larger techbio financings and enabling aggressive asset licensing. Total funding above $600M and strategic capital from Sanofi signal strong financial support for scaling.

Strategic Partnerships: Entered a first-of-its-kind three-way collaboration with Sanofi and OpenAI to build AI software for drug development, indicating differentiated platform recognition. Additional marquee transactions with Sanofi (e.g., gusacitinib license) reinforce high-signal partner engagement.

Product Line Growth: Multiple sizable deals expanded and activated the portfolio, including licensing gusacitinib to Sanofi and acquiring a TYK2 inhibitor via Bleecker Bio and an oral miR-124 activator via Kenmare Bio. Public coverage cites several active clinical programs, including one in Phase 3, consistent with ongoing pipeline buildout.

Investor Backing & Capital Strength: Advent International’s definitive agreement in August 2025 to acquire the company is presented as a strong signal of confidence in its leadership and growth prospects. The pending acquisition is framed around accelerating network expansion and product innovation.

Strong Market Position & Advantage: Independent and association coverage describes PatientPoint as operating the nation’s largest connected digital device network in tens of thousands of physician offices, bolstered by its 2021 combination with Outcome Health. Multiple sources characterize its leadership in terms of network size and advertiser reach.

Product Line Growth: Recent launches such as the Consumer Health Network and programmatic “Health Audiences” indicate expansion beyond traditional in‑office media into data‑driven activation. Partnerships and new offerings oriented to measurable outcomes suggest ongoing product momentum.

Market Expansion: Public materials highlight growth from roughly 2,500+ to 5,500–6,000+ research sites across 50+ countries and an increase to 25+ sponsors on the platform. Feedback suggests the marketplace is scaling on both the supply (sites) and demand (sponsors) sides.

Strategic Partnerships: Named collaborations with AbbVie, Sanofi, and Moderna, plus integrations with RealTime‑Devana and CRIO, demonstrate blue‑chip adoption and expanding ecosystem reach. Feedback suggests repeated use on consequential trials and data‑sharing ties are strengthening commercial durability.

Innovation-Driven Growth: Recent launches such as AI Site Selection and AI patient pre‑screening target bottlenecks in planning, site selection, and enrollment. External recognition (e.g., Fast Company’s Most Innovative Companies with adoption more than doubling in 2023) signals momentum behind product innovation.

Strong Revenue Growth: Recent results show net revenue increased year over year to about $3.02 billion in 2025, with 2026 guidance indicating continued albeit modest expansion. Q4 momentum and management commentary point to ongoing top-line gains supported by launches across segments.

Profitability: The company returned to GAAP profitability in 2025 and expanded adjusted EBITDA, with leverage trending lower after refinancing. Management highlights improving margins and cash generation into 2026.

Diversified Revenue Streams: All three segments—Affordable Medicines, Specialty, and AvKARE—contributed to growth in 2025, while biosimilars and complex products add higher‑value mix alongside branded therapies. Public‑sector initiatives (e.g., CalRx naloxone) and government distribution broaden end‑market exposure.